Ethiopian Airlines has transported 3.5 million doses of COVID-19 vaccine from Shanghai to São Paulo, Brazil, via Addis Ababa
- Ethiopian Airlines joined the fight against the pandemic since the outbreak of the virus
- Ethiopian Airlines has beefed up its cargo shipment capacity by reconfiguring its
- passenger aircraft
- Ethiopian played an exemplary role in the distribution of PPE across the globe
Ethiopian Airlines Group, Africa’s leading Airline, has transported 3.5 Million doses
of COVID-19 vaccine from Shanghai to São Paulo, Brazil, via Addis Ababa. The vaccine arrived in Brazil on Thursday, 15 April 2021. So far, Ethiopian Cargo and Logistics Services has transported over 20 Million vaccines to more than 20 countries.
Ethiopian Airlines Group CEO Mr. Tewolde GebreMariam said “As a leading pan
African airline, we joined the fight against the pandemic since the outbreak of the virus. Our commitment to fighting against the pandemic and saving lives has been unwavering in Africa and beyond. I feel that our efficient and timely delivery of vaccines would save millions of lives that could have been lost due to lack of access to vaccines. We are devoted to transport vaccines globally with our modern fleet, well-established infrastructure and diligent employees. I am glad that we have started to reach beyond Africa and we will continue to play our part in the global
vaccine distribution. Our collaborative efforts are the only way out at this critical time where equitable distribution and transportation of the vaccines is desirable.’’
Ethiopian Airlines has beefed up its cargo shipment capacity by reconfiguring its
passenger aircraft and introducing new technologies. The airline has become the choice of cargo partners as a result of its agility, capability to store and carry time-sensitive shipments such as pharmaceuticals. It played an exemplary role in the distribution of PPE across the globe which led to the selection of Addis Ababa Bole International Airport as a humanitarian air hub by UN agencies.
Currently, Ethiopian is developing an in-house dry ice manufacturing facility that is
capable of producing 9,000kg of ice daily to fulfill the need for additional coolants for vaccines produced by Pfizer-BioNTech & Moderna that require ultra-cold environment for transport.
